Oxigene Inc (OXGN) 2.83 $OXGN
Metastatic Prostate Cancer - Pipeline Review, H1 2014: 9 Companies and 16 Drugs Profiled
M2 - Mon May 12, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f52w3s/metastatic) has announced the addition of the "Metastatic Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agonox - Camurus AB - Colby Pharmaceutical Company - Fountain Biopharma Inc. - MEI Pharma, Inc. - OXiGENE, Inc. - Progenics Pharmaceuticals, Inc. Drug Profiles: - cabazitaxel - pracinostat - leuprolide acetate - LU-901 - veliparib - Engineered Autologous T Cells [cyclophosphamide] - MEDI-6469 - CPC-410 - Actimab-P - Peptide to Inhibit MT1 MMP for Autoimmune Disorders, Inflammation and Oncology - MIP-1095 - FB-704A - Ceramide Analogs - KGP-94 - Vaccine For Oncolytic Newcastle Disease Virus - Glutathione Disulfide Liposomal For more information visit http://www.researchandmarkets.com/research/f52w3s/metastatic
Medullary Thyroid Cancer - Pipeline Review, H1 2014
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/htrmtc/medullary_thyroid) has announced the addition of the "Medullary Thyroid Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Medullary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Medullary Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Medullary Thyroid Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Medullary Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Medullary Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - AstraZeneca PLC - Novartis AG - Exelixis, Inc. - Ariad Pharmaceuticals, Inc. - OXiGENE, Inc. - Nerviano Medical Sciences S.r.l. - Globeimmune, Inc. - Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/ht...ry_thyroid
OXiGENE Reports First Quarter 2014 Financial Results
GlobeNewswire - Tue May 06, 3:23PM CDT
Company Strengthens Cash Position by $20 Million
OXiGENE Announces First Quarter 2014 Earnings Conference Call and Webcast
GlobeNewswire - Tue Apr 22, 3:30PM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report first quarter 2014 results on Tuesday May 6, 2014. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm ET (1:30 p.m. PT).
Stocks Review on Top Gainers -- Research on Uranium Energy, EarthLink Holdings, Tarena Intl., and OXiGENE
PR Newswire - Tue Apr 22, 7:26AM CDT
The US markets saw a positive sentiment on Monday, April 21, 2014, with the NASDAQ Composite closing at 4,121.55, up 0.64%, the Dow Jones Industrial Average ending the session at 16,449.25, up 0.25%, and the S&P 500 gained 0.38%, to finish the trading session at 1,871.89. The gains were broad based as eight out of ten sectors ended the session in positive. A number of stocks saw large movements, including Uranium Energy Corp. (NYSE MKT: UEC), EarthLink Holdings Corp. (NASDAQ: ELNK), Tarena International Inc. (NASDAQ: TEDU) and OXiGENE Inc. (NASDAQ: OXGN). Free technical research on UEC, ELNK, TEDU and OXGN can be downloaded upon signing up at:
OXiGENE Announces Results of Promising Preclinical Studies at 2014 AACR Conference
GlobeNewswire - Mon Apr 07, 9:00AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced results from three preclinical studies related to its ongoing research and development programs. The data are being presented this week at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, California.
Top Gainers Updates -- Research on Sangamo BioSciences, Synthesis Energy Systems, OXiGENE, and Affymetrix
PR Newswire - Tue Apr 01, 8:08AM CDT
On Monday, March 31, 2014, the US markets saw a positive sentiment, as the NASDAQ Composite closed at 4,198.99, up 1.04%, the Dow Jones Industrial Average ended the session at 16,457.66, up 0.82% and the S&P 500 edged 0.79% higher to finish the trading session at 1,872.34. The gains were broad based as nine out of 10 sectors ended the session in positive. A number of stocks saw large movements, including Sangamo BioSciences Inc. (NASDAQ: SGMO), Synthesis Energy Systems Inc. (NASDAQ: SYMX), OXiGENE Inc. (NASDAQ: OXGN) and Affymetrix Inc. (NASDAQ: AFFX). Free technical research on SGMO, SYMX, OXGN and AFFX can be downloaded upon signing up at:
Celsius Holdings Inc.'s Stock Volume Falls amid Minimal News
ACCESSWIRE - Tue Apr 01, 8:01AM CDT
Boca Raton, Fla.-based beverage company Celsius Holdings Inc.'s (OTCPINK: CELH) stock volume was low Mar. 31, with just 8,555 shares changing hands, less than half its three-month average volume of 18,039.
OXiGENE Announces Presentation of Three Preclinical Abstracts at 2014 AACR Conference
GlobeNewswire - Thu Mar 27, 7:30AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced that data from three studies related to its early stage scientific programs will be presented at the Annual Meeting of the American Association of Cancer Research (AACR) being held April 5-9, 2014 at the San Diego Convention Center in San Diego, CA.
3 Biotech Stocks Under $10 to Trade
at The Street - Wed Mar 26, 5:00AM CDT
Keep your eye on these under-$10 biotech stocks.
Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'
at The Street - Fri Mar 21, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
OxiGene (OXGN) Marked As A Dead Cat Bounce Stock
at The Street - Wed Mar 19, 8:51AM CDT
Trade-Ideas LLC identified OxiGene (OXGN) as a "dead cat bounce" (down big yesterday but up big today) candidate
OXiGENE posts higher net loss of USD8.3m for 2013
M2 - Wed Mar 19, 5:47AM CDT
Biopharmaceutical company OXiGENE (NasdaqCM:OXGN) on Tuesday reported a net loss of USD8.3m for the year ended 31 December 2013.
OXiGENE Reports Full Year 2013 Financial Results
GlobeNewswire - Tue Mar 18, 3:00PM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial results for the year ended December 31, 2013.
Technical Summary - Most Active Equities: Symantec, Mobile Telesystems, Allied Nevada Gold, and OXiGENE
PR Newswire - Fri Mar 14, 7:25AM CDT
The trading session on Thursday, March 13, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,108.89, down 1.41% and the NASDAQ Composite closed at 4,260.42, down 1.46%. The S&P 500 finished the session 1.17% lower at 1,846.34. The losses were broad based as nine of ten sectors ended the session in negative. Investor-Edge.com looks at some of the equities which were most active during the session. These include Symantec Corp. (NASDAQ:SYMC), Mobile Telesystems OJSC (NYSE:MBT), Allied Nevada Gold Corp. (NYSE MKT:ANV), and OXiGENE Inc. (NASDAQ:OXGN). Free research on these four companies can be accessed at:
Investment Grants, Data Presentations, Clinical Study Results, and Collaborative Programs - Analyst Notes on UnitedHealth Group, Bristol-Myers Squibb, AbbVie, Cigna, and OXiGENE
PR Newswire - Fri Mar 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding UnitedHealth Group Incorporated (NYSE: UNH), Bristol-Myers Squibb Company (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Cigna Corporation (NYSE: CI), and OXiGENE, Inc. (NASDAQ: OXGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
SmarTrend Watching for Potential Pullback in Shares of OXiGENE After 77.27% Gain
Comtex SmarTrend(R) - Wed Mar 12, 5:13PM CDT
OXiGENE (NASDAQ:OXGN) traded in a range yesterday that spanned from a low of $4.14 to a high of $5.40. Yesterday, the shares gained 77.3%, which took the trading range above the 3-day high of $2.45 on volume of 29.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Nasdaq stocks posting largest volume increases
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Small-Cap Biotech on the Verge of a Breakout: ABIO
at The Street - Wed Mar 12, 12:43PM CDT
Here's how to trade Arca Biopharma.
Metastatic Prostate Cancer - Pipeline Review, H1 2014: 9 Companies and 16 Drugs Profiled
M2 - Mon May 12, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f52w3s/metastatic) has announced the addition of the "Metastatic Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agonox - Camurus AB - Colby Pharmaceutical Company - Fountain Biopharma Inc. - MEI Pharma, Inc. - OXiGENE, Inc. - Progenics Pharmaceuticals, Inc. Drug Profiles: - cabazitaxel - pracinostat - leuprolide acetate - LU-901 - veliparib - Engineered Autologous T Cells [cyclophosphamide] - MEDI-6469 - CPC-410 - Actimab-P - Peptide to Inhibit MT1 MMP for Autoimmune Disorders, Inflammation and Oncology - MIP-1095 - FB-704A - Ceramide Analogs - KGP-94 - Vaccine For Oncolytic Newcastle Disease Virus - Glutathione Disulfide Liposomal For more information visit http://www.researchandmarkets.com/research/f52w3s/metastatic
Medullary Thyroid Cancer - Pipeline Review, H1 2014
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/htrmtc/medullary_thyroid) has announced the addition of the "Medullary Thyroid Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Medullary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Medullary Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Medullary Thyroid Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Medullary Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Medullary Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - AstraZeneca PLC - Novartis AG - Exelixis, Inc. - Ariad Pharmaceuticals, Inc. - OXiGENE, Inc. - Nerviano Medical Sciences S.r.l. - Globeimmune, Inc. - Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/ht...ry_thyroid
OXiGENE Reports First Quarter 2014 Financial Results
GlobeNewswire - Tue May 06, 3:23PM CDT
Company Strengthens Cash Position by $20 Million
OXiGENE Announces First Quarter 2014 Earnings Conference Call and Webcast
GlobeNewswire - Tue Apr 22, 3:30PM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report first quarter 2014 results on Tuesday May 6, 2014. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm ET (1:30 p.m. PT).
Stocks Review on Top Gainers -- Research on Uranium Energy, EarthLink Holdings, Tarena Intl., and OXiGENE
PR Newswire - Tue Apr 22, 7:26AM CDT
The US markets saw a positive sentiment on Monday, April 21, 2014, with the NASDAQ Composite closing at 4,121.55, up 0.64%, the Dow Jones Industrial Average ending the session at 16,449.25, up 0.25%, and the S&P 500 gained 0.38%, to finish the trading session at 1,871.89. The gains were broad based as eight out of ten sectors ended the session in positive. A number of stocks saw large movements, including Uranium Energy Corp. (NYSE MKT: UEC), EarthLink Holdings Corp. (NASDAQ: ELNK), Tarena International Inc. (NASDAQ: TEDU) and OXiGENE Inc. (NASDAQ: OXGN). Free technical research on UEC, ELNK, TEDU and OXGN can be downloaded upon signing up at:
OXiGENE Announces Results of Promising Preclinical Studies at 2014 AACR Conference
GlobeNewswire - Mon Apr 07, 9:00AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced results from three preclinical studies related to its ongoing research and development programs. The data are being presented this week at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, California.
Top Gainers Updates -- Research on Sangamo BioSciences, Synthesis Energy Systems, OXiGENE, and Affymetrix
PR Newswire - Tue Apr 01, 8:08AM CDT
On Monday, March 31, 2014, the US markets saw a positive sentiment, as the NASDAQ Composite closed at 4,198.99, up 1.04%, the Dow Jones Industrial Average ended the session at 16,457.66, up 0.82% and the S&P 500 edged 0.79% higher to finish the trading session at 1,872.34. The gains were broad based as nine out of 10 sectors ended the session in positive. A number of stocks saw large movements, including Sangamo BioSciences Inc. (NASDAQ: SGMO), Synthesis Energy Systems Inc. (NASDAQ: SYMX), OXiGENE Inc. (NASDAQ: OXGN) and Affymetrix Inc. (NASDAQ: AFFX). Free technical research on SGMO, SYMX, OXGN and AFFX can be downloaded upon signing up at:
Celsius Holdings Inc.'s Stock Volume Falls amid Minimal News
ACCESSWIRE - Tue Apr 01, 8:01AM CDT
Boca Raton, Fla.-based beverage company Celsius Holdings Inc.'s (OTCPINK: CELH) stock volume was low Mar. 31, with just 8,555 shares changing hands, less than half its three-month average volume of 18,039.
OXiGENE Announces Presentation of Three Preclinical Abstracts at 2014 AACR Conference
GlobeNewswire - Thu Mar 27, 7:30AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced that data from three studies related to its early stage scientific programs will be presented at the Annual Meeting of the American Association of Cancer Research (AACR) being held April 5-9, 2014 at the San Diego Convention Center in San Diego, CA.
3 Biotech Stocks Under $10 to Trade
at The Street - Wed Mar 26, 5:00AM CDT
Keep your eye on these under-$10 biotech stocks.
Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'
at The Street - Fri Mar 21, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
OxiGene (OXGN) Marked As A Dead Cat Bounce Stock
at The Street - Wed Mar 19, 8:51AM CDT
Trade-Ideas LLC identified OxiGene (OXGN) as a "dead cat bounce" (down big yesterday but up big today) candidate
OXiGENE posts higher net loss of USD8.3m for 2013
M2 - Wed Mar 19, 5:47AM CDT
Biopharmaceutical company OXiGENE (NasdaqCM:OXGN) on Tuesday reported a net loss of USD8.3m for the year ended 31 December 2013.
OXiGENE Reports Full Year 2013 Financial Results
GlobeNewswire - Tue Mar 18, 3:00PM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial results for the year ended December 31, 2013.
Technical Summary - Most Active Equities: Symantec, Mobile Telesystems, Allied Nevada Gold, and OXiGENE
PR Newswire - Fri Mar 14, 7:25AM CDT
The trading session on Thursday, March 13, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,108.89, down 1.41% and the NASDAQ Composite closed at 4,260.42, down 1.46%. The S&P 500 finished the session 1.17% lower at 1,846.34. The losses were broad based as nine of ten sectors ended the session in negative. Investor-Edge.com looks at some of the equities which were most active during the session. These include Symantec Corp. (NASDAQ:SYMC), Mobile Telesystems OJSC (NYSE:MBT), Allied Nevada Gold Corp. (NYSE MKT:ANV), and OXiGENE Inc. (NASDAQ:OXGN). Free research on these four companies can be accessed at:
Investment Grants, Data Presentations, Clinical Study Results, and Collaborative Programs - Analyst Notes on UnitedHealth Group, Bristol-Myers Squibb, AbbVie, Cigna, and OXiGENE
PR Newswire - Fri Mar 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding UnitedHealth Group Incorporated (NYSE: UNH), Bristol-Myers Squibb Company (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Cigna Corporation (NYSE: CI), and OXiGENE, Inc. (NASDAQ: OXGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
SmarTrend Watching for Potential Pullback in Shares of OXiGENE After 77.27% Gain
Comtex SmarTrend(R) - Wed Mar 12, 5:13PM CDT
OXiGENE (NASDAQ:OXGN) traded in a range yesterday that spanned from a low of $4.14 to a high of $5.40. Yesterday, the shares gained 77.3%, which took the trading range above the 3-day high of $2.45 on volume of 29.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Nasdaq stocks posting largest volume increases
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Small-Cap Biotech on the Verge of a Breakout: ABIO
at The Street - Wed Mar 12, 12:43PM CDT
Here's how to trade Arca Biopharma.
